期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

新辅助内分泌治疗绝经后乳腺癌的临床疗效观察 被引量：2

The clinical curative effect of neoadjuvant endocrine therapy postmenopausal breast cancer
在线阅读 下载PDF
导出
摘要 目的观察和探讨新辅助内分泌治疗绝经后乳腺癌的临床疗效和应用价值。方法对56例绝经后乳腺癌患者应用新辅助内分泌治疗,疗效达CR(完全缓解)、PR(部分缓解)或SD(稳定)则继续进行治疗,直至病情出现PD(进展)或主动提出终止内分泌治疗,再给予手术治疗。结果所有患者中CR 6例,PR 29例,总有效率(CR+PR)为62.5%;不同受体阳性患者中,以ER、PR双阳性疗效最好,有效率为78.38%。结论新辅助内分泌治疗用于治疗绝经后激素受体阳性的乳腺癌患者有明显疗效,副作用小,具有在临床上推广的价值。 Objective To observation and explore neoadjuvant endocrine therapy the clinical curative effect of post - menopausal breast cancer and application value. Methods 56 eases postmenopansal breast cancer patients were applying neoadjuvant endocrine therapy, when curative effect was complete remission, partial remission or stable, continuing to treatment, until the illness appeared progress or patients offering to stop endocrine therapy, surgical treatment. Results 6 cases of com- plete remission ,29 case of partial remission , the total effective rate was 62. 5% ; Different receptor positive patients, with ER PR double positive effect for the best, efficient 78. 38%. Conclusion New New adjuvant endocrine therapy used to treat postmenopansal hormone receptor - positive breast cancer patients have apparent curative effect, side effect was small, has the value of clinical promotion.
作者 林春平
机构地区 广东省揭阳市人民医院
出处 《中国医学创新》 CAS 2011年第16期5-6,共2页 Medical Innovation of China
关键词 新辅助内分泌治疗 乳腺癌 绝经 临床疗效 Neoadjuvant endocrine therapy Breast cancer Postmenopausal Clinical effect
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献9

二级参考文献64

  • 1Dixon JM, Anderson TJ, Miller WR. Neoadjuvant endocrine therapy of breast cancer : a surgical perspective. Eur J Cancer, 2002,38 ( 17 ) :2214-2221.
  • 2Hoff PM,Valero V, Buzdar AU, et al. Combined modality treatment of locally advanced breast carcinoma in elderly patients or patients with severe comorbid conditions using tamoxifen as the primary therapy. Cancer,2000,88(9):2054-2060.
  • 3Dixon JM, Love CD, Bellamy CO, et al. Izetrozole as primary medical therapy for locally advanced and large operable breast cancer. Breast Cancer Res Treat,2001,66 ( 3 ) : 191-199.
  • 4Eiermann W, Paepke S, Appfelstaedt J,et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized doable-blind multicen|er study. Ann Oncol, 2001,12 ( 11 ) : 1527-1532.
  • 5Ellis MJ, Coop A, Singh B,et. al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB- 1 and/or ErbB-2 positive, estrogen receptor positive primary breast cancer: evidence from a phase Ⅲ randomized trial. J Clin Oncol,2001,19(18) :3808-3816.
  • 6Milla Santos A, Milla L, Cairo N, et al. Anastrozole as neoadjuvant therapy for patients with hormone- dependent, locally- advanced breast cancer. Anticancer Res,2004,24 (2C) : 1315-1318.
  • 7Dixon JM, Renshaw L, Bellamy C, et al. The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: a randomized, double-blind, single-center study. Clin Cancer Res,2000,6(6) :2229-2235.
  • 8Miller WR, Dixon JM. Endocrine and clinical endpoints of exemestane as neoadjuvant therapy. Cancer Control,2002,9(2 Suppl) :9-15.
  • 9Saji S, Hirose M, Toi M. Novel sensitizing agents: potential contribution of COX-2 inhibitor for endocrine therapy of breast cancer. Breast Cancer, 2004,11(2) :129-133.
  • 10Chow LW, Wong JL, Toi M. Celecoxib anti-aromatase neoadjuvant(CAAN) trial for locally advanced breast cancer: preliminary report. J Steroid Biochem Mol Biol, 2003,86(3-5 ) :443-447.

共引文献28

同被引文献19

  • 1Jordan V C. Tamoxifen: a most unlikely pioneering medicine[J]. Nat Rev Drug Discov, 2003, 2(3):205.
  • 2Gradishar W J. Recently initiated studies: neoadjuvant treatments in next century[J]. Semi Oncol, 1999, 26(1 suppl 3):26.
  • 3Valenzuela M, Julian T B. Neo-adjuvant hormonal therapy[J]. Breast J, 2008, 14(3):279-283.
  • 4Bross P F, Baird A, Chen G, et al. Fulvestrant in postmenopausal women with advanced breast cancer[J]. Clin Cancer Res, 2003, 9(12):4309-4317.
  • 5Miller W R, Dixon J M. Local endocrine effects of aromatase inhibitors within the berast[J]. J SteroidBiochem Mol Biol, 2001, 79(1-5):93.
  • 6Krainick-Strobel U E, Lich tenegger W, Wallwiener D, et al. Neoadjuvant let rozole in postmenopausal estrogen and/or progesterone recept or positive breast cancer: a phase II b/ E trial to invest igateoptimal duration of preoperative endocrine therapy[J]. BMC Cancer, 2008, 26(8):62.
  • 7Fan J, Yin W J, Lu J S, et al. ER alpha negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor[J]. Cancer Res Clin Oncol, 2008, 134(1):883-890.
  • 8Borgquist S, Holm C, Stendahl M, et al. Oestrogen receptors alpha and beta show different associations to clinicopathological parameters and their co-expression might predict a better response to endocrine treatment in breast cancer[J]. J Clin Pathol, 2008, 61(2):197-203.
  • 9Perey L, Paridaens R, Hawle H. Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatas.e inhibitors: final results of phase ]I Swiss Group for Clinical Cancer Research TriaI(SAK21/00)[J]. Ann Oncol, 2007, 18(1):64-69.
  • 10Macedo L F, Sabnis G J, Goloubeva 0 G, et al. Combination of anastrozole with fulvestrant in the intratumoral aromatase xenograft model[J]. Cancer Res, 2008, 68(9):3516-3522.

引证文献2

二级引证文献4

中国医学创新
2011年 第16期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部